menu

Confronting the Complexities of Reaching LDL-C Thresholds in Patients with Primary Hyperlipidemia

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Confronting the Complexities of Reaching LDL-C Thresholds in Patients with Primary Hyperlipidemia

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

How can we help patients with primary hyperlipidemia who struggle to reach their recommended LDL-C target? Tune in.

  • Sponsored by

  • Overview

    The Phase 3 trials for LEQVIO®(inclisiran) demonstrated powerful and consistent LDL-C reduction throughout each of the six-month dosing intervals after two initial doses.1 So when should we consider LEQVIO as a treatment option? Tune in to hear clinical considerations in recognizing appropriate patients for this treatment option with Dr Michael Bloch, Vascular Medicine Specialist and Clinical Lipidologist who directs a large multidisciplinary vascular medicine and lipid clinic in Reno, Nevada.

    Reference
    1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp.

    Dr Bloch has been compensated for his time.

  • INDICATION

    LEQVIO® (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

  • IMPORTANT SAFETY INFORMATION

    Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

    Please click here for LEQVIO full Prescribing Information.

    2/24      318298

Schedule24 Apr 2024